.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Gastrointestinal (GI) cancers impose a significant health burden globally, particularly affecting the population in India. Consequently, understanding the Galectin-3 GI cancer biomarker remains vital for improving diagnosis and patient outcomes. The LGALS3 gene encodes this multifunctional protein, which regulates cell adhesion and immune responses. Moreover, recent bioinformatic mapping reveals distinct expression patterns that influence tumor progression.
Specifically, the study indicates that LGALS3 shows significant upregulation in cholangiocarcinoma, esophageal adenocarcinoma, and liver hepatocellular carcinoma. Conversely, researchers observed downregulation in colon and rectal adenocarcinomas. These findings are important because high Galectin-3 levels often predict poorer survival rates, especially in liver and pancreatic cancers. In addition, the protein fosters an immunosuppressive tumor microenvironment. Therefore, clinicians can utilize this information to identify high-risk patients more accurately.
Protein-protein interaction analysis identifies MAPK3 and PTEN as key partners for Galectin-3. Furthermore, gene enrichment data highlights its involvement in T-cell activation and motility regulation. Thus, targeting this protein might enhance the efficacy of current immunotherapies by preventing tumor immune escape. In conclusion, Galectin-3 serves as both a diagnostic tool and a promising therapeutic target for advanced GI malignancies.
Galectin-3 serves as a significant prognostic indicator. High expression levels in liver and pancreatic cancers correlate with advanced disease stages and lower survival rates.
This protein contributes to an immunosuppressive microenvironment. It regulates T-cell activation and allows tumor cells to evade the body's natural defenses more effectively.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Chiriva-Internati M et al. Galectin 3 expression in gastrointestinal tumors identified through comprehensive bioinformatic mapping. Discov Oncol. 2026 Jun 10. doi: 10.1007/s12672-026-04931-3. PMID: 42268362.
Song L, et al. Galectin-3 in cancer: Fondness and functions. J Hematol Oncol. 2014;7:77. doi: 10.1186/s13045-014-0077-0.
Scafetta G, et al. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. J Exp Clin Cancer Res. 2024;43:41. doi: 10.1186/s13046-024-02968-2.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive bioinformatic mapping study has identified Galectin-3 (LGALS3) as a critical prognostic biomarker across seven gastrointestinal cancers. Elevated expression correlates with poor survival and an immunosuppressive environment, suggesting its potential as a targeted therapeutic option.
4 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
